Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04948619 · ClinicalTrials.gov registry record · Phase 2
Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients
A Phase 2 study of Pediatric Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04948619 is a Phase 2 study of Pediatric Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 64 participants, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04948619, a Phase 2 study of Pediatric Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applicable. The investigators will also restart vaccinations at earlier time points than previously studied, at 3 months post therapy, and will assess whether boosters or revaccination schedules are superior for regaining immunity against potentially serious infections in survivors.
Conditions Studied
Interventions
- BIOLOGICAL Vaccine
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2030-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04948619
The ClinicalTrials.gov registry entry for NCT04948619 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,489-participant average among 51 other Pediatric Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pediatric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Vaccine is the first listed.
NCT04948619 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT04948619 about?
NCT04948619 is a clinical study titled "Immune Function and Response to Vaccination After Cancer Therapy in Pediatric Patients". Pediatric cancer survivors have increased infection-related morbidity and mortality. This study will evaluate immune dysfunction following cancer directed systemic therapy completion, with attention to clinical relevance and infection rate in this population compared to healthy siblings, when applic...
What is the current status of trial NCT04948619?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2022-08-08. Estimated completion is 2030-10.
What conditions does trial NCT04948619 study?
This clinical trial studies the following conditions: Pediatric Cancer.
What interventions are being tested in trial NCT04948619?
The interventions under investigation include: Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04948619?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04948619 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
RECRUITING · Phase 2
-
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
LIFE Cancer Survivorship Database for Pediatric Cancer
RECRUITING
-
Multisite Implementation of COMPRENDO
RECRUITING · NA
-
Childhood Cancer Predisposition Study (CCPS)
RECRUITING
-
Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.